AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-02-01

Reporting Person: Crowley John F (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-01	Common Stock	M	83333	$6.10	Acquired	1095389	Direct
2023-02-01	Common Stock	M	56596	$5.13	Acquired	1151985	Direct
2023-02-01	Common Stock	S	147316	$13.1102	Disposed	1004669	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Stock Options (right to buy)	$6.10	M	83333	Disposed	2026-06-15	Common Stock (83333)	Direct
2023-02-01	Stock Options (right to buy)	$5.13	M	56596	Disposed	2027-01-03	Common Stock (56596)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022 for estate planning purposes.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.81 to $13.28 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of these options were fully vested and exercisable as of the transaction date.